Cephalon completes takeover of Mepha

Cephalon has completed its acquisition of the Swiss pharmaceutical company Mepha in a deal which sees the firm become a wholly-owned subsidiary.

The newly-purchased firm creates and commercialises branded and generic products in more than 50 different countries and has been bought for 662.4 million Swiss francs (404.3 million pounds).

This payment includes certain closing adjustments and will also be subject to further post-closing working capital and net debt adjustments.

Cephalon has expressed confidence that the closure of the deal will allow the firm to expand its international presence and strengthen its position in the generics market.

Dr Frank Baldino Jr, chairman and chief executive officer of Cephalon, added: “We are proud to include Mepha as part of the Cephalon family. Mepha has a strong reputation for high-quality products and services that deliver value to patients and healthcare professionals.”

This comes after the company last week completed a takeover of Ception Therapeutics, which will allow the firm to offer more biologic pharmaceutical products.